Aquatic Capital Management LLC Buys Shares of 35,501 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Aquatic Capital Management LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 35,501 shares of the biopharmaceutical company’s stock, valued at approximately $1,697,000.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after acquiring an additional 386,618 shares during the last quarter. Snyder Capital Management L P raised its holdings in shares of Halozyme Therapeutics by 2.6% during the fourth quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock valued at $199,294,000 after acquiring an additional 105,086 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 2.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after acquiring an additional 47,795 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock valued at $85,254,000 after purchasing an additional 9,780 shares during the last quarter. Finally, Norges Bank purchased a new position in Halozyme Therapeutics during the fourth quarter worth approximately $60,054,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO opened at $60.82 on Wednesday. The stock’s 50-day moving average price is $60.63 and its 200 day moving average price is $55.24. Halozyme Therapeutics, Inc. has a 12-month low of $37.97 and a 12-month high of $66.00. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company’s stock, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,697 shares of company stock valued at $1,558,052. 2.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark restated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.